Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

Grzegorz S. Nowakowski; Annalisa Chiappella; Thomas E. Witzig; David W. Scott; Michele Spina; Randy D. Gascoyne; Lei Zhang; Jacqueline Russo; Janet Kang; Jingshan Zhang; Yingyong Xu; Umberto Vitolo

doi:10.3324/haematol.2019.220475

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Thomas E. Witzig, David W. Scott, Michele Spina, Randy D. Gascoyne, Lei Zhang, Jacqueline Russo, Janet Kang, Jingshan Zhang, Yingyong Xu, Umberto Vitolo

Hematology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	E72-E75
Journal	Haematologica
Volume	105
Issue number	2
DOIs	https://doi.org/10.3324/haematol.2019.220475
State	Published - Jan 31 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2019.220475

Cite this

Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. / Nowakowski, Grzegorz S.; Chiappella, Annalisa; Witzig, Thomas E.; Scott, David W.; Spina, Michele; Gascoyne, Randy D.; Zhang, Lei; Russo, Jacqueline; Kang, Janet; Zhang, Jingshan; Xu, Yingyong; Vitolo, Umberto.

In: Haematologica, Vol. 105, No. 2, 31.01.2020, p. E72-E75.

Research output: Contribution to journal › Letter › peer-review

Nowakowski, Grzegorz S. ; Chiappella, Annalisa ; Witzig, Thomas E. ; Scott, David W. ; Spina, Michele ; Gascoyne, Randy D. ; Zhang, Lei ; Russo, Jacqueline ; Kang, Janet ; Zhang, Jingshan ; Xu, Yingyong ; Vitolo, Umberto. / Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. In: Haematologica. 2020 ; Vol. 105, No. 2. pp. E72-E75.

@article{9062a7aec2fc491fb527611a193f20d8,

title = "Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma",

author = "Nowakowski, {Grzegorz S.} and Annalisa Chiappella and Witzig, {Thomas E.} and Scott, {David W.} and Michele Spina and Gascoyne, {Randy D.} and Lei Zhang and Jacqueline Russo and Janet Kang and Jingshan Zhang and Yingyong Xu and Umberto Vitolo",

note = "Funding Information: 1Division of Hematology, Mayo Clinic, Rochester, MN, USA; 2Division of Hematology, Citt{\`a} della Salute e della Scienza Hospital and University, Torino, Italy; 3Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada; 4Division of Medical Oncology A, National Cancer Institute, Aviano, Italy and 5Celgene Corporation, Summit, NJ; USA Acknowledgments: we thank all of the co-investigators on the ROBUST clinical study; patients, families, and caregivers who are participating in the study; and support from Celgene Corporation for sponsoring the study. This work was supported by Celgene Corporation, Summit, NJ, USA and is a joint scientific collaboration Funding Information: among Fondazione Italiana Linfomi, Mayo Clinic, and Celgene. Editorial support was provided by Julie Kern, PhD, CMPP of Bio Connections LLC and funded by Celgene Corporation. The authors directed development of the manuscript and are fully responsible for all content and editorial decisions.",

year = "2020",

month = jan,

day = "31",

doi = "10.3324/haematol.2019.220475",

language = "English (US)",

volume = "105",

pages = "E72--E75",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "2",

}

TY - JOUR

T1 - Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma

AU - Nowakowski, Grzegorz S.

AU - Chiappella, Annalisa

AU - Witzig, Thomas E.

AU - Scott, David W.

AU - Spina, Michele

AU - Gascoyne, Randy D.

AU - Zhang, Lei

AU - Russo, Jacqueline

AU - Kang, Janet

AU - Zhang, Jingshan

AU - Xu, Yingyong

AU - Vitolo, Umberto

N1 - Funding Information: 1Division of Hematology, Mayo Clinic, Rochester, MN, USA; 2Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy; 3Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada; 4Division of Medical Oncology A, National Cancer Institute, Aviano, Italy and 5Celgene Corporation, Summit, NJ; USA Acknowledgments: we thank all of the co-investigators on the ROBUST clinical study; patients, families, and caregivers who are participating in the study; and support from Celgene Corporation for sponsoring the study. This work was supported by Celgene Corporation, Summit, NJ, USA and is a joint scientific collaboration Funding Information: among Fondazione Italiana Linfomi, Mayo Clinic, and Celgene. Editorial support was provided by Julie Kern, PhD, CMPP of Bio Connections LLC and funded by Celgene Corporation. The authors directed development of the manuscript and are fully responsible for all content and editorial decisions.

PY - 2020/1/31

Y1 - 2020/1/31

UR - http://www.scopus.com/inward/record.url?scp=85078815823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078815823&partnerID=8YFLogxK

U2 - 10.3324/haematol.2019.220475

DO - 10.3324/haematol.2019.220475

M3 - Letter

C2 - 31221781

AN - SCOPUS:85078815823

VL - 105

SP - E72-E75

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -